Humacyte uses smooth muscle cells isolated from cadavers to create a collagen matrix. The cells are grown on a biodegradable scaffold for 8-10 weeks. The original scaffold degrades, leaving just the cells and the collagen matrix. In a final step, researchers remove the cells and leave only the matrix. Without the cells, the non-immunogenic matrix can be used as a 'universal' off-the-shelf medical device. It can be grown in tube, sheet, or particulate form. Once implanted, host cells infiltrate, which then integrate and remodel the graft as if it were a natural body part.
21 Davis Drive
Suite 140
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
EFPIA says reforms make the continent less attractive for innovative firms.
J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.
EFPIA says reforms make the continent less attractive for innovative firms.
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
